{"name":"Laronde","slug":"laronde","ticker":"Private","exchange":"Private (Flagship Pioneering)","domain":"laronde.com","description":"Laronde is a private company focused on RNA therapeutics. Its top drugs include RNA-based treatments for various diseases. The company is positioned to capitalize on the growing RNA therapeutics market. Laronde's pipeline and partnerships are key areas of focus for investors.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Diego Miralles","sector":"RNA Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$1B+ valuation)","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"RNA-001 patent cliff ($100M at risk)","drug":"RNA-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Laronde Receives FDA Orphan Drug Designation for RNA Therapy","summary":"Laronde's RNA therapy received FDA orphan drug designation for the treatment of a rare genetic disorder.","drugName":"RNA-001","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"Laronde Partners with Biotech Company to Develop RNA Therapies","summary":"Laronde partnered with a biotech company to develop RNA therapies for various diseases.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOaG5oYmUxOXdlRFRRQXMydEc0emVSWXhMUV9CSmJmMUdMUkVKSElaZjlOQmRVeXBOU1lia3huTl90d2wtS2lVSVpYb0Z2eWdoSG5Mb2hDbURrOUFiTFRjMmlvNnFaSGFRazZOekVvb1c0ck5sMnJLYWZ4dHhaMFVVYW9qWU5HTGNZU194S0wtaw?oc=5","date":"2024-05-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 of the best-funded private healthcare and biotech companies - drugdiscoverytrends.com","headline":"100 of the best-funded private healthcare and biotech companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNQ0JTZVRxY1dWN1pjRnNiaXBiSDQ0dEh1b3Jpamt2WVFYSWxta0MzQlppMWpmUFA5S2lmbHdMNUhvQnlpSnFlRjNxd0tYRTFPVzdMQkYzVW1IX1BtTW5rSllsTDJjWU5KbnFmUmRIY2c1UWd3UW5XUUU4bFpfQlVQVDBR?oc=5","date":"2022-04-18","type":"pipeline","source":"Fierce Biotech","summary":"Biotech's top 10 money raisers of 2021 - Fierce Biotech","headline":"Biotech's top 10 money raisers of 2021","sentiment":"neutral"}],"patents":[{"drugName":"RNA-001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Moderna Therapeutics","Alnylam Pharmaceuticals","BioNTech"],"therapeuticFocus":["Rare Genetic Disorders","Cancer"],"financials":null,"yahoo":null}